alzheon, Author at Alzheon | Preserving Future Memories - Page 10 of 21

About alzheon

This author has not yet filled in any details.
So far alzheon has created 202 blog entries.

11 Nov, 2020

Breakthrough in the race for an Alzheimer’s drug

alzheon2024-08-09T11:10:21-04:00November 11th, 2020|Tags: BNN|

27 Oct, 2020

Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer’s Disease

alzheon2024-08-26T10:55:47-04:00October 27th, 2020|Tags: PR|

20 Aug, 2020

Biotechs Tap Growing U.S. Government Support for Alzheimer’s Research

alzheon2021-08-19T10:20:44-04:00August 20th, 2020|Tags: WSJ|

20 Aug, 2020

Alzheon receives $47M NIH grant funding its phase III Alzheimer’s study

alzheon2020-08-21T21:04:15-04:00August 20th, 2020|Tags: BioWorld|

20 Aug, 2020

Boost for Alzheon’s targeted Alzheimer’s candidate

alzheon2020-08-21T21:39:34-04:00August 20th, 2020|Tags: thepharmaletter|

20 Aug, 2020

NIA Backs Alzheon’s Phase III Alzheimer’s Trial with $47 Million Grant

alzheon2020-08-21T21:40:29-04:00August 20th, 2020|Tags: BioSpace.com|

20 Aug, 2020

Alzheon Awarded $47 Million Grant from U.S. National Institute on Aging for Phase 3 Clinical Study of ALZ-801, an Oral Treatment for Alzheimer’s Disease

alzheon2024-08-05T19:24:36-04:00August 20th, 2020|Tags: PR|

17 Aug, 2020

Peer-Reviewed Scientific Publication Profiles First Wave of Disease-Modifying Alzheimer’s Treatments with Potential for Near Term Approval: Aducanumab, Gantenerumab, BAN2401 and ALZ-801

alzheon2024-08-12T10:15:30-04:00August 17th, 2020|

17 Aug, 2020

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid targeting drugs for Alzheimer’s disease with potential for near term approval

alzheon2024-06-19T18:00:43-04:00August 17th, 2020|

5 Feb, 2020

Targeting Amyloid Oligomers for Alzheimer’s Research

alzheon2020-08-21T20:13:44-04:00February 5th, 2020|